



10006277, 051702

Express Mail Label No.: EU206590371

US

Date of Deposit: May 17, 2002

Attorney Docket No. VPI/99-06 CON

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Francesco Salituro et al.,  
ASSIGNEE: Vertex Pharmaceuticals Incorporated  
SERIAL NUMBER: 10/008,277 EXAMINER: Not Yet Assigned  
FILING DATE: December 3, 2002 ART UNIT: Not Yet Assigned  
FOR: INHIBITORS OF c-JUN N-TERMINAL (JNK) KINASES

May 17, 2002  
Cambridge, Massachusetts

Box SEQUENCE  
Assistant Commissioner for Patents  
Washington, D.C. 20231

**SUBMISSION OF PAPER COPY AND/OR COMPUTER-READABLE  
COPY OF SEQUENCE LISTING FOR INVENTION CONTAINING  
NUCLEOTIDE AND/OR AMINO ACID SEQUENCE**

1. ☒ This paper is in response to the Patent Office letter dated May 8, 2002.  
☒ A copy of the Patent Office letter is enclosed.  
*Note: If these papers are filed before the Patent Office letter is mailed, the adequate identification of the original papers should be made, e.g., in addition to the name of the inventor and title of the invention, the filing date on the Express Mail Label, the USSN from the return postcard or the attorney's docket number must be added.*  
☒ This paper is in compliance with the requirements for patent applications containing nucleotide sequences and/or amino acid sequence disclosures.
2. Submitted herewith are:  
☐ A Preliminary Amendment directing entry of the Sequence Listing into the specification;  
☒ a paper copy of the Sequence Listing for the above-identified patent application with each sequence assigned a separate identifier; and  
☒ a copy of the Sequence Listing in computer-readable form for the above-identified patent application.

APPLICANTS:  
U.S.S.N.:


3. **Statement:**

I hereby state that: *(complete applicable items - A, B and/or C)*

- A. ☒ The content of the paper and computer-readable copies of the Sequence Listing submitted herewith are the same.
- B. ☐ The content of the computer-readable copy of the Sequence Listing submitted herewith is the same as the Sequence Listing appearing at the end of the originally-filed specification.
- C. ☒ This submission includes no new matter.

Applicants believe that no fee is required for the filing of the present submission. However, the Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment, to Deposit Account No. 50-0725, Ref. No. VPI/99-06 CON.

Respectfully submitted,

  
\_\_\_\_\_  
Andrea L.C. Robidoux  
Reg. No. 47,902  
Agent for Applicants

c/o Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, Massachusetts 02139-4242  
Tel: (617) 444-6731  
Fax: (617) 444-6483

Dated: May 17, 2002

TRADOCS:1253257.1(QV0P011.DOC)



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/008,277	12/03/2001	Francesco Salituro	VPI/99-06 CON

Tina Powers  
VERTEX PHARMACEUTICALS INC.  
130 Waverly Street  
Cambridge, MA 02139-4242

CONFIRMATION NO. 5437

## FORMALITIES LETTER



\*OC000000008062793\*

Date Mailed: 05/08/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



10/0018-2-77 1151262


0300

Certificate Of-Mailing Under 37 CFR 1.10

Express Mailing No. EU206590371US Date of Deposit May 17, 2002

I hereby certify that this document/application is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington D.C. 20231

Angela J. Billings  
(type or printed name of person mailing document/applications)

  
(signature of person mailing document/application)

1. Certificate of Mailing
2. Transmittal Letter for Submission of Sequence Listing
3. Verified Statement Under 37 C.F.R. §1.821 (f)
4. Sequence Listing w/Diskette
5. Copy of Notice to Comply with Requirements
6. Return Receipt Postcard



04-15-02

03CO

VPI/99-06 CONIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Salituro et al.  
Serial No.: 10/008,277  
Filing Date: December 3, 2001 (03.12.01)  
For: INHIBITORS OF c-JUN N-TERMINAL  
KINASES

Cambridge, Massachusetts  
April 12, 2002

Hon. Assistant Commissioner  
For Patents  
Washington, D.C. 20231

Attention: Application Processing Division,  
Special Processing and Correspondence Branch

TRANSMITTAL LETTER FOR NOTICE TO FILE CORRECTED  
APPLICATION PAPERS

Sir:


Transmitted herewith in response to the Notice  
To File Corrected Application Papers - Filing Date  
Granted, mailed February 14, 2002, are the following  
materials relating to the above-identified application:

1. Transmittal letter for Notice To File  
Corrected Application Papers
2. Notice To File Corrected Application  
Papers
3. Response to Notice To File Corrected  
Application Papers
4. Preliminary Amendment

5. Replacement Specification pages 2-33
6. Sequence Listing & Diskette
7. Verified Statement Under 37 C.F.R.
8. Executed Declaration and Power of Attorney
9. Certificate of Mailing
10. Return Receipt Postcard

Applicant's believe that no additional fees are due at this time however, the Commissioner is hereby authorized to charge payment of additional fees required under 37 C.F.R. § 1.16 in connection with the paper transmitted herewith, or credit any overpayment of same, to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,



April 12, 2002  
Date

Andrea L.C. Robidoux  
(Reg.No. 47,902)  
Agent for Applicants  
C/O Vertex Pharmaceuticals Inc.  
130 Waverly Street  
Cambridge, MA 02139-4242  
Tel: (617) 444-6731  
Fax: (617) 444-6483



VPI/99-06 CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Salituro et al.  
Serial No.: 10/008,277  
Filing Date: December 3, 2001 (03.12.01)  
For: INHIBITORS OF c-JUN N-TERMINAL  
KINASES

Cambridge, Massachusetts  
April 12, 2002

Hon. Assistant Commissioner  
For Patents  
Washington, D.C. 20231

Attention: Application Processing Division,  
Special Processing and Correspondence Branch

RESPONSE TO NOTICE TO FILE CORRECTED APPLICATION PAPERS

Sir:

This is in response to the Notice To File Corrected Application Papers - Filing Date Granted, mailed February 14, 2002 ("the Notice"). The Notice indicates that the application is informal as filed and the following items are required:

- (a) substitute Specification pages 2-33 in compliance with 37 C.F.R. § 1.52; and
- (b) a Sequence Listing pursuant to 37 C.F.R. §§ 1.821-1.825.

Applicants submit herewith the required Sequence Listing and statement pursuant to 37 C.F.R. §§ 1.821-1.825. Applicants also submit a Preliminary

Amendment, filed concurrently herewith, directing the entry of the Sequence Listing into the application.

Applicants also submit herewith substitute Specification pages 2-33 in compliance with 37 C.F.R. § 1.52. The substitute specification contains no new matter.

Applicant's believe that no additional fees are due at this time however, the Commissioner is hereby authorized to charge payment of additional fees required under 37 C.F.R. § 1.16 in connection with the paper transmitted herewith, or credit any overpayment of same, to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,



---

Andrea L.C. Robidoux  
(Reg.No. 47,902)  
Agent for Applicants  
C/O Vertex Pharmaceuticals Inc.  
130 Waverly Street  
Cambridge, MA 02139-4242  
Tel: (617) 444-6731  
Fax: (617) 444-6483





04-15-02

10008277-053702

03CO

**Certificate Of Mailing Under 37 CFR 1.10**

Express Mailing No. EU206590924US Date of Deposit April 12, 2002

I hereby certify that this document/application is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington D.C. 20231

Angela J. Billings  
(type or printed name of person mailing document/applications)

(signature of person mailing document/application)

1. Transmittal Letter for Notice to File Corrected Papers
2. Notice to File Corrected Papers
3. Response to Notice to File Corrected Papers
4. Preliminary Amendment
5. Replacement Specification pages 2-33
6. Sequence Listing & Diskette
7. Verified Statement Under 37 C.F.R.
8. Copy of Executed Declaration and Power of Attorney
9. Certificate of Mailing
10. Return Receipt Postcard